Promotes and distributes frequency rhythmic electrical modulation system (FREMSTM) equipment. Focuses on equipment used in the treatment of peripheral neuropathy. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $802K against $0 in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0002. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 7.9 times as much as the market average. Big rallies — and big drops — can both happen fast.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the growth trend, earnings execution, the revenue breakdown.